Gastric Hepatoid Adenocarcinoma: A Case Report and Literature Update

Öz

Hepatoid adenocarcinomas (HAC) are very rare extrahepatic tumours that have very poor prognosis. The majority of these tumors are recognized by the height in serum AFP. The incidence rate for reported gastric tumours from the Far East is between 1,3% and 15% but there are only case reports available from other regions. There are two types of HAC: well-differentiated papillary/tubular type and medullary type with polygonal cells. AFP, CEA, CK7, and CK20 have effects on survival. HAC is treated in the way traditional gastric adenocarcinomas are treated. Hepatoid adenocarcinoma of the stomach has poor prognosis. It is often metastatic at diagnosis with an average life expectancy of 4,7 months. Here, we present a rare case of a chemotherapy-resistant patient diagnosed with hepatoid adenocarcinoma in our clinic.

Key Word: Hepatoid Adenocarcinoma; AFP; HCC.

Anahtar Kelimeler

• -

Journal of Turgut Ozal Medical Center

Öz

Hepatoid adenokarsinomalar (HAC) çok nadir rastlanan ve oldukça kötü prognozlu ekstrahepatik tümörlerdir. Bu tümörlerin büyük çoğunluğu serumda AFP yüksekliği ile tanınmaktadır. İnsidansı en sık görüldüğü Uzakdoğu için gastrik tümörlerin %1,3–15 olarak bildirilmiş, diğer bölgelerden vakalar şeklinde bildirim mevcuttur. İyi differansiye papiller/tubuler ve poligonal hücrelerden oluşan medüller tip olmak üzere iki tipi tanımlanmıştır. AFP, CEA, CK7 ve CK20 nin survi üzerine etkisi gösterilmiştir. HAC lar da klasik mide adenokarsinomaları gibi tedavi edilmeye çalışılır. Adjuvan kemo-radyoterapi verilebilir. Midenin hepatoid adenokanseri kötü prognozludur. Genellikle tanı konduğunda metastatik olup, ortalama yaşam beklentisi 4,7 aydır. Burada kliniğimizde hepatoid adenokarsinoma tanısı koyduğumuz ve kemoterapiye dirençli hastamızı nadir rastlanması sebebi ile sunduk

Anahtar Kelimeler

• Hepatoid Adenokarsinom, AFP, HCC

Kaynakça

1. Su JS, Chen YT, Wang RC, Wu CY, Lee SW, Lee TY. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review. World J Gastroenterol 2013;19:321-7.
2. Liu X, Sheng W, Wang Y. An analysis of clinicopathological features and prognosis by comparing hepatoid adenocarcinoma of the stomach with AFP-producing gastric cancer. J Surg Oncol 2012;106:299-303.
3. Ishicura H, Fukosawa Y, Ogasawara K, Natori T, Tsukada Y, Aizawa M. An AFP producing gastric carcinoma with features of hepatic differentiation:a case report. Cancer 1985;56:840-8.
4. Bakır T, Aliyazicioğlu Y, Bektaş A, Siviloglu C, Ozgur O. Hepatoid adenocarcinoma of the stomach, report of five cases and review of the literature. Acta Gastroenterol 2006;69:330-7.
5. Inagawa S, Shimazaki J, Hori M et al. Hepatoid adenocarcinoma of the stomach: case report. Gastric Cancer 2001;4:43-52.
6. Gálvez-Muñoz E, Gallego-Plazas J, Gonzalez-Orozco V et al. Hepatoid adenocarcinoma of the stomach–a different histology for not so different gastric adenocarcinoma: a case report. Int Semin Surg Oncol 2009;6:13.
7. Yang J, Wang Rui, Zhang W, Zhuang W, Wang M, Tang C. Clinicopathological and Prognostic Characteristics of hepatoid adenocarcinoma of The stomach. Hindawi 2014;1-5.
8. Gao YB, Zhang DF, Jin XL, Xiao JC. Preliminary study on the clinical and pathological relevance of gastric hepatatoid adenocarcinoma. J dig dis 2007;8:23-8.

9. Sentani K, Oue N, Sakamoto N, Arihiro K, Aoyagi K, Sasaki H. et al. Gene expression profiling with microarray and SAGE identifieas PLUNC as a marker for hepatoid adenocarcinoma of the stomach. Mod pathol 2008;21:464-75.
10. Wöhrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004;15:1585-95.
11. Takeyema H, Sawai H Wakasugi T, Takahashi H, Matsuo Y, Ochi N et al. Successful Paclitaxel- based chemotheraphy for an alpha- fetoprotein- producing gastric cancer patient with multipl liver metastases. World J Surg oncol 2007;5:79-83.